GlaxoSmithKline to Acquire Cancer Biotech TESARO for $5.1 Billion
GlaxoSmithKline to Acquire Cancer Biotech TESARO for $5.1 Billion
The purchase aims to build GSK’s oncology pipeline.
GlaxoSmithKline to Acquire Cancer Biotech TESARO for $5.1 Billion
GlaxoSmithKline to Acquire Cancer Biotech TESARO for $5.1 Billion

The purchase aims to build GSK’s oncology pipeline.

The purchase aims to build GSK’s oncology pipeline.

PARP inhibitor
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.